by Team Small News | Dec 27, 2025 | Glenmark, Pharma
Glenmark Pharmaceuticals Inc, USA, has launched Epinephrine Injection USP, a bioequivalent and therapeutically equivalent product to the reference listed drug manufactured by BPI Labs, LLC. The product is available in a 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial and is... by Team Small News | Dec 18, 2025 | Glenmark, Pharma
Glenmark Specialty S.A., a subsidiary of India-based Glenmark Pharmaceuticals, has entered into a licensing agreement with China’s Jiangsu Hansoh Pharmaceutical Group Co. for the oncology drug Aumolertinib. The agreement grants Glenmark exclusive rights to... by Team Small News | Dec 10, 2025 | Glenmark, Pharma
Glenmark Pharmaceuticals Inc. has issued a recall of over 11,100 bottles of its blood pressure medication, Ziac, due to potential cross-contamination with another drug. The medication, which is used to treat high blood pressure, also known as hypertension, may contain... by Team Small News | Dec 4, 2025 | Glenmark, Pharma
Glenmark Pharmaceuticals has significantly expanded its presence in the “High Latin America” region, which includes Mexico, Colombia, Ecuador, Peru, Central America, and the Caribbean, over the past four years. The company’s growth in this region has... by Team Small News | Dec 2, 2025 | Glenmark, Pharma
Glenmark Pharmaceuticals, a prominent drugmaker, has successfully completed a pre-approval inspection by the U.S. Food and Drug Administration (FDA) at its formulations manufacturing facility in Chhatrapati Sambhajinagar, Maharashtra. The inspection, which took place...
by Team Small News | Nov 12, 2025 | Glenmark, Pharma, Zydus
Zydus Lifesciences and Glenmark Pharmaceuticals have both received approvals from China’s National Medical Products Administration (NMPA) for their respective products. Zydus Lifesciences has been granted approval for Venlafaxine Extended-Release (ER) Capsules,...